Home > Oncology > Entrectinib promising for brain metastases in NTRK fusion-positive solid tumors

Entrectinib promising for brain metastases in NTRK fusion-positive solid tumors


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
Clinical Cancer Research
Reuters Health - 21/02/2022 - Entrectinib, an inhibitor of tropomyosin receptor kinases (TRKA)/B/C and ROS1, showed promise in patients with metastatic NTRK fusion-positive solid tumors with central nervous system (CNS) involvement in an updated analysis. Entrectinib, marketed as Roslytek by Genentech, is approved in the U.S. and Europe for the treatment of patients ages 12 and up with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non-small cell lung cancer. An earlier integrated analysis of three previous phase I/II trials showed that entrectinib yielded durable overall and intracranial responses in 54 patients with NTRK fusion-positive solid tumors, including rare tumor types, Dr. Christian Rolfo of the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York City and colleagues note in Clinical Cancer Research. The current study expands prior reports with additional patients and longer follow-up. "What is interes...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on